The Role and Mechanism of SGLT2 Inhibitors in Chronic Kidney Disease
- 1Department of Nephrology, The Second Affiliated Hospital, Shantou University Medical College, Shantou, 515041, People’s Republic of China
Abstract
Chronic kidney disease (CKD) refers to structural or functional abnormalities of the kidneys caused by various factors lasting ≥3 months, or a decline in glomerular filtration rate (GFR) of <60 mL/min of unknown cause lasting ≥3 months. Its primary causes include diabetic kidney disease, hypertensive nephropathy, IgA nephropathy, membranous nephropathy, and lupus nephritis, among others. As a new class of antidiabetic drugs, sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown in numerous clinical studies and animal experiments to be effective in treating CKD of various etiologies. The renoprotective effects of SGLT2 inhibitors are independent of their glucose-lowering effects. Through mechanisms such as hemodynamics, oxidative stress, and anti-fibrosis, they reduce serum creatinine and urinary protein levels, thereby slowing the progression of CKD. This review primarily summarizes clinical and basic research on SGLT2i in the treatment of CKD and analyzes the signaling pathways through which SGLT2i exerts its effects on CKD. This demonstrates that SGLT2 inhibitors can delay the progression of kidney function decline and improve outcomes in patients across various subtypes through multiple mechanisms. They are suitable for patients with CKD of different etiologies and across different estimated glomerular filtration rate (eGFR) categories, indicating the significant potential and promising prospects for the widespread use of SGLT2 inhibitors in patients with CKD.
Related
- SGLT2 inhibitors attenuate diabetic kidney disease by suppressing YAP dependent ferroptosis
- Individual-Level Counterfactual Analysis of SGLT2 Inhibitors Versus DPP4 Inhibitors in Diabetic Kidney Disease Using Causal Machine Learning
- SGLT2 inhibitors and exercise in diabetic kidney disease: mechanistic rationale, emerging clinical evidence, and future perspectives.
- Distinct temporal neuropsychiatric outcomes associated with GLP-1 receptor agonists versus SGLT2 inhibitors after acute kidney disease in type 2 diabetes
- Effectiveness of Adding GLP‐1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study
BibTeX
@article{xie2026role,
title = {{The Role and Mechanism of SGLT2 Inhibitors in Chronic Kidney Disease}},
author = {Jiaqian Xie and Yuqi Liu and Yi Zhao and Ying Wang and Tianbiao Zhou},
journal = {Drug Design, Development and Therapy},
year = {2026},
month = oct,
doi = {10.2147/dddt.s648280},
url = {https://doi.org/10.2147/dddt.s648280},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - The Role and Mechanism of SGLT2 Inhibitors in Chronic Kidney Disease
AU - Jiaqian Xie
AU - Yuqi Liu
AU - Yi Zhao
AU - Ying Wang
AU - Tianbiao Zhou
PY - 2026
DA - 2026/10/21
JO - Drug Design, Development and Therapy
DO - 10.2147/dddt.s648280
UR - https://doi.org/10.2147/dddt.s648280
AB - Chronic kidney disease (CKD) refers to structural or functional abnormalities of the kidneys caused by various factors lasting ≥3 months, or a decline in glomerular filtration rate (GFR) of <60 mL/min of unknown cause lasting ≥3 months. Its primary causes include diabetic kidney disease, hypertensive nephropathy, IgA nephropathy, membranous nephropathy, and lupus nephritis, among others. As a new class of antidiabetic drugs, sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been shown in numerous clinical studies and animal experiments to be effective in treating CKD of various etiologies. The renoprotective effects of SGLT2 inhibitors are independent of their glucose-lowering effects. Through mechanisms such as hemodynamics, oxidative stress, and anti-fibrosis, they reduce serum creatinine and urinary protein levels, thereby slowing the progression of CKD. This review primarily summarizes clinical and basic research on SGLT2i in the treatment of CKD and analyzes the signaling pathways through which SGLT2i exerts its effects on CKD. This demonstrates that SGLT2 inhibitors can delay the progression of kidney function decline and improve outcomes in patients across various subtypes through multiple mechanisms. They are suitable for patients with CKD of different etiologies and across different estimated glomerular filtration rate (eGFR) categories, indicating the significant potential and promising prospects for the widespread use of SGLT2 inhibitors in patients with CKD.
SN - 1177-8881
ER -